Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
July 29, 2022
Share
Hunan Jiudian Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 1,030.56 million compared to CNY 731.27 million a year ago. Revenue was CNY 1,030.96 million compared to CNY 731.74 million a year ago. Net income was CNY 129.77 million compared to CNY 112.82 million a year ago. Basic earnings per share from continuing operations was CNY 0.39 compared to CNY 0.34 a year ago. Diluted earnings per share from continuing operations was CNY 0.39 compared to CNY 0.34 a year ago.
Hunan Jiudian Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of pharmaceutical preparations. The Companyâs products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The Company sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.